Janux Therapeutics (JANX) Stock Price, News & Analysis

Company Overview

Janux Therapeutics, Inc. (NASDAQ: JANX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the body’s T cells against cancer while limiting activity in healthy tissues. The company’s approach is intended to address challenges associated with conventional T-cell engagers, including systemic toxicity and limited tolerability.

Janux’s programs are based on its Tumor Activated T Cell Engager (TRACTr) platform. These therapeutic molecules are designed to remain inactive in circulation and become activated within the tumor microenvironment, where they can direct T cells to recognize and attack cancer cells. The company is developing candidates for solid tumors, including JANX007, a prostate-specific membrane antigen-directed program, and JANX008, an epidermal growth factor receptor-directed program.

Founded in 2017 and headquartered in San Diego, California, Janux Therapeutics serves the global oncology drug-development market through its research and clinical development activities. The company is led by David A. Campbell, Ph.D., who serves as president and chief executive officer. Janux became a publicly traded company on the Nasdaq under the symbol JANX in 2024.

Key Stats

• Today's Range: $16.76 to $17.35
• 50-Day Range: $14.96 to $20.24
• 52-Week Range: $12.12 to $35.34
• Volume: 407,255 shs
• Average Volume: 1.09 million shs
• Market Capitalization: $1.04 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.46
• Consensus Rating: Moderate Buy

Janux Therapeutics Stock Analysis - MarketRank™

Janux Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 489th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Janux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 10 buy ratings, 2 hold ratings, and 2 sell ratings.

Upside Potential

Janux Therapeutics has a consensus price target of $36.46, representing about 115.9% upside from its current price of $16.89.

Amount of Analyst Coverage

Janux Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.70) to ($2.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Janux Therapeutics is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Janux Therapeutics is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Janux Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.46% of the float of Janux Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Janux Therapeutics has a short interest ratio ("days to cover") of 5.89.

Change versus previous month

Short interest in Janux Therapeutics has recently decreased by 2.83%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Janux Therapeutics does not currently pay a dividend.

Dividend Growth

Janux Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.67

News Sentiment

Janux Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Janux Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

5 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Janux Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.90% of the stock of Janux Therapeutics is held by insiders.

Percentage Held by Institutions

75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:JANX
• CIK: 1817713
• Web: www.januxrx.com
• Phone: 858-751-4493
• Fax: N/A
• Employees: 113
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Janux Therapeutics: $36.46
• High Price Target: $100.00
• Low Price Target: $14.00
• Potential Upside/Downside: +116.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.62 million
• Net Margins: N/A
• Pretax Margin: -427.47%
• Return on Equity: -11.89%
• Return on Assets: -11.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.35
• Quick Ratio: 16.35

Sales & Book Value

• Annual Sales: $10 million
• Price / Sales: 103.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.91 per share
• Price / Book: 1.06

Miscellaneous

• Outstanding Shares: 61,140,000
• Free Float: 56,307,000
• Market Cap: $1.03 billion
• Optionable: Optionable
• Beta: 2.53